Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 TherapyL. Dousset, Lise Boussemart, Solène‐Florence Kammerer‐Jacquet et al.|JCO Precision Oncology|2021Cited by 61
Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanomaMarine Rousset, Mathiéu Molimard, Caroline Dutriaux et al.|Clinica Chimica Acta|2017Cited by 36
Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinomaJulie Valentin, Anne Pham‐Ledard, E. Gérard et al.|Journal of Geriatric Oncology|2021Cited by 32
Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional studyL. Dousset, Julien Sénéschal, E. Gérard et al.|JAAD International|2021Cited by 27
Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanomaVaianu Leroy, Anne Pham‐Ledard, E. Gérard et al.|Cancer Immunology Immunotherapy|2019Cited by 22